CN Patent

CN113384546A — 鲁索利替尼的缓释剂型

Assigned to Incyte Corp · Expires 2021-09-14 · 5y expired

What this patent protects

本发明涉及鲁索利替尼或其药学上可接受的盐的缓释制剂和剂型，它们可用于治疗詹纳斯激酶相关疾病，例如骨髓增生性病症。

USPTO Abstract

本发明涉及鲁索利替尼或其药学上可接受的盐的缓释制剂和剂型，它们可用于治疗詹纳斯激酶相关疾病，例如骨髓增生性病症。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN113384546A
Jurisdiction: CN
Classification: —
Expires: 2021-09-14
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.